title: Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats.
abstract: The present study was designed to investigate the pharmacokinetics and acute cardiotoxicity of doxorubicin (DOX) after intravenous (i.v.) administration (15 mg kg(-1)) to streptozotocin (STZ)-induced hyperglycaemic and normoglycaemic male Wistar albino rats. In STZ diabetic rats the area under the serum DOX time-concentration curve (AUC(0-24 h)) increased (13.35+/-1.33 compared with 7.13+/-0.71 microg h(-1) ml(-1); P<0.0001) and plasma and renal DOX clearance decreased. The DOX accumulation in STZ-induced diabetic rat heart (12.7+/-1.2 microg g(-1)) was increased (P<0.05) compared with non-diabetic hearts (11.0+/-0.9 microg/g), 24 h after DOX administration. Serum creatine phosphokinase (CPK) activity showed 25% increase in peak level in STZ diabetic rats compared to non-diabetic rats. DOX produced a reduction in heart rate of anaesthetized non-diabetic (20%) and diabetic (14%) rats 1 and 2 h after its administration, respectively. Isolated atria of diabetic rats were more sensitive to the negative chronotropic effect of DOX (150 microm). These preliminary results indicate that hyperglycaemia may alter the pharmacokinetics and acute cardiotoxicity of DOX and suggest that i.v. doses of DOX in diabetic patients may need to be modified if the present data could be extrapolated to humans.
authors.affiliation: Department of Pharmacology,College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
authors.forename: O A
authors.initials: OA
authors.lastname: Al-Shabanah
authors.forename: H A
authors.initials: HA
authors.lastname: El-Kashef
authors.forename: O A
authors.initials: OA
authors.lastname: Badary
authors.forename: A M
authors.initials: AM
authors.lastname: Al-Bekairi
authors.forename: M M
authors.initials: MM
authors.lastname: Elmazar
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D001786:Blood Glucose / Q000032:analysis; D003402:Creatine Kinase / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000633:toxicity; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
chemical_list: D000903:Antibiotics, Antineoplastic; D001786:Blood Glucose; D013311:Streptozocin; D004317:Doxorubicin; D003402:Creatine Kinase